Triple Negative Breast Neoplasms Clinical Trials

62 clinical trials for Triple Negative Breast Neoplasms across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) — RECRUITING · PHASE3
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) — RECRUITING · PHASE3
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of LY4170156 in Participants With Selected Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Pembrolizumab and Cryoablation in People With Breast Cancer — RECRUITING · PHASE1
• A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer — RECRUITING · PHASE1
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer — RECRUITING · PHASE2
• Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery — RECRUITING · PHASE2
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer — RECRUITING · PHASE2
• Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer — RECRUITING · PHASE2
• Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy — RECRUITING · PHASE2
• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer — NOT_YET_RECRUITING · PHASE2
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss — TERMINATED · PHASE3
• A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. — NOT_YET_RECRUITING · PHASE2
• Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) — COMPLETED · PHASE2
• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors — TERMINATED · PHASE1
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer — TERMINATED · PHASE2
• Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC — ACTIVE_NOT_RECRUITING · PHASE3
• Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer — COMPLETED · PHASE1
• Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab — COMPLETED · PHASE3
• Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer — COMPLETED · PHASE3
• NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors — TERMINATED · PHASE1
• Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) — COMPLETED · PHASE1
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) — COMPLETED · PHASE3
• A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors — TERMINATED · PHASE1
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC — ACTIVE_NOT_RECRUITING · PHASE3
• Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC — TERMINATED · PHASE1
• A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC — NOT_YET_RECRUITING · PHASE2
• A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers — COMPLETED · PHASE1
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) — COMPLETED · PHASE2
• Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment — TERMINATED
• "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer — TERMINATED · PHASE1
• First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours — COMPLETED · PHASE1
• Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy — TERMINATED · PHASE1
• Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study — WITHDRAWN · NA
• Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease — OTHER · PHASE2
• Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial — OTHER · PHASE2
• Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer — TERMINATED · PHASE2
• A Safety Study of SGN-LIV1A in Breast Cancer Patients — COMPLETED · PHASE1
• A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors — TERMINATED · PHASE1
• Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity — TERMINATED · PHASE2
• Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR — TERMINATED · PHASE2
• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) — TERMINATED · PHASE2
• Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy — WITHDRAWN · PHASE1

Refine this search